Indivior Pharmaceuticals Inc (INDV) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	1.3B	1.2B	1.2B	1.1B	901.0M
Cost of Revenue	215.0M	246.0M	231.0M	174.0M	151.0M
Gross Profit	1.1B	993.0M	957.0M	919.0M	750.0M
Operating Expenses
R&D Expense	65.0M	97.0M	107.0M	116.0M	74.0M
SG&A Expense	534.0M	634.0M	618.0M	569.0M	469.0M
General & Admin Expense	—	319.0M	363.0M	333.0M	251.0M
Selling & Marketing Expense	—	315.0M	255.0M	236.0M	218.0M
Other Expenses	—	(3.0M)	200.0M	390.0M	288.0M
Total Operating Expenses	599.0M	728.0M	925.0M	1.1B	831.0M
Cost and Expenses	814.0M	974.0M	1.2B	1.2B	982.0M
Operating Income (EBIT)	518.0M	265.0M	32.0M	(156.0M)	(81.0M)
Non-Operating
Interest Income	18.0M	22.0M	23.0M	43.0M	19.0M
Interest Expense	27.0M	45.0M	41.0M	35.0M	29.0M
Net Interest Income	(9.0M)	(23.0M)	(18.0M)	8.0M	(10.0M)
Other Non-Op Income/Expense	(125.0M)	(26.0M)	(18.0M)	7.0M	(8.0M)
Non-Operating Income (excl Interest)	98.0M	(19.0M)	(23.0M)	(42.0M)	(19.0M)
EBT (Pre-Tax Income)	393.0M	239.0M	14.0M	(149.0M)	(89.0M)
Income Tax Expense	38.0M	29.0M	11.0M	(20.0M)	(44.0M)
Bottom Line
Net Income	355.0M	210.0M	2.0M	(129.0M)	(44.0M)
Earnings from Cont. Ops	355.0M	210.0M	3.0M	(129.0M)	(45.0M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	355.0M	210.0M	2.0M	(129.0M)	(44.0M)
Per Share
Basic EPS	$2.84	$1.68	$0.02	($0.94)	($0.37)
Diluted EPS	$2.79	$1.64	$0.02	($0.91)	($0.37)
Revenue Per Share	$10.63	$9.91	$9.00	$7.96	$6.48
Shares
Basic Shares Outstanding	125.4M	125.0M	132.0M	137.3M	139.0M
Diluted Shares Outstanding	129.0M	128.0M	133.0M	141.8M	139.0M
Profitability Metrics
EBITDA	432.0M	304.0M	84.0M	(99.0M)	(46.0M)
D&A	12.0M	20.0M	29.0M	15.0M	16.0M
EBIT	420.0M	284.0M	55.0M	(114.0M)	(62.0M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026